Are the new weight loss injections actually safe?

The biggest misconception: 'new' does not mean 'untested'

When people ask whether the weight loss injection is safe and how that question is properly answered, the worry is often that these treatments are experimental or rushed. That is understandable, the medicines reached mainstream awareness quickly and the media coverage has been loud. The facts are less dramatic. Tirzepatide was studied across the SURMOUNT clinical programme involving thousands of adults before NICE recommended it in December 2024 (published as TA1026). Semaglutide completed phase-3 trials, including STEP 1, before its own NICE appraisal. Both hold full MHRA marketing authorisations, and both carry Black Triangle status, meaning safety data is still actively collected, not because regulators are worried, but because that is standard practice for newer medicines. 'New' and 'unstudied' are not the same thing.

What the trials showed, and what ongoing pharmacovigilance continues to show, is a side-effect profile that is real but mostly manageable. The NHS tirzepatide page summarises the known effects clearly, and it is worth reading before you start. Most of what people experience relates to the gut; the serious events are infrequent and, critically, recognisable.

Side effects: what to expect and when to be concerned

Nausea is the effect patients mention most. It tends to arrive in the first week or two, peaks around a dose increase, and fades as the body adjusts. Loose stools, constipation, burping, and a general feeling of fullness that borders on queasiness are also common. Headache, fatigue and some dizziness appear in a smaller proportion of users. Injection-site redness or mild discomfort is possible, rotating sites between the abdomen, thigh and upper arm helps reduce that. A question our prescribers hear most weeks is whether nausea means the treatment is not working or should be stopped; usually it means the dose has landed and the body needs a short settling period.

Serious but infrequent events deserve clear attention rather than alarm. The MHRA's January 2026 Drug Safety Update singled out acute pancreatitis: persistent, severe abdominal pain that reaches into the back, with or without vomiting, should prompt an immediate call to 111 or a visit to A&E. Gallbladder problems, significant dehydration from prolonged vomiting or diarrhoea, and signs of an allergic reaction (swelling, breathing difficulty) are also in the 'seek help now' category. Patients with a history of pancreatitis, medullary thyroid carcinoma or MEN2 should discuss those histories with a prescriber before any prescription is issued.

If you want to explore how the safety picture compares across different injection options, that page goes deeper on both medicines side by side.

When to get medical help, and how to report

Seek urgent medical attention if you experience severe stomach pain that does not ease and spreads to your back; repeated vomiting that stops you keeping fluids down; signs of a serious allergic reaction; or sudden changes in vision. These are uncommon, but they are not trivial and they are time-sensitive.

For less urgent concerns (ongoing nausea that is affecting your quality of life, constipation that is not resolving, or anything else that does not feel right) contact your prescribing service. At nume that means our aftercare team, available seven days a week.

Every patient can also report suspected side effects directly to the MHRA via the Yellow Card scheme. That reporting feeds into the ongoing safety surveillance that keeps medicines data current. If you are unsure whether what you are experiencing is a side effect worth reporting, report it anyway, the scheme welcomes all submissions, not just confirmed cases.

The supply chain question: where 'safe' gets complicated

The clinical evidence for these medicines is robust when they are genuine, correctly stored and prescribed appropriately. The danger arises when counterfeit or unlicensed products enter the picture. The MHRA has confirmed enforcement actions involving approximately 20 million doses of illegally traded weight-loss medicines, worth an estimated £45 million, seized in 2025 alone. A raid in Northampton uncovered the UK's first illicit manufacturing site producing fake tirzepatide pens. Some seized products have contained insulin rather than the stated active ingredient.

The only reliable way to check a supplier is to look them up on the GPhC pharmacy register. A registered pharmacy dispenses against a valid prescription issued by a regulated prescriber. If you want to read more about what the new weight loss injection options actually involve and how they are regulated, that page sets out the key details clearly. For more on where to buy weight loss injections safely, that page covers what to check before you commit to any provider.

At nume, every prescription is written by a GPhC-registered Independent Prescriber who reviews your consultation personally. Our prescribers discuss safety, eligibility and side effects as part of that process, and if you have questions about whether the new weight loss injections are safe for someone in your situation, that is exactly what the consultation is designed to address. If you want to understand your own suitability, the starting point is a free consultation, there is no obligation, and suitability is always a clinical call, not an automated one.